Skip to main content
. 2013 May 23;8(5):e63933. doi: 10.1371/journal.pone.0063933

Figure 4. Enhanced survival of brain-tumour bearing mice co-transferred with tumour-antigen specific CD4 and CD8 T cells.

Figure 4

In vitro activated OT-I CD8 T cells and polarised OT-II CD4 T cells were intravenously transferred into C57BL/6 mice that had been intracranially implanted with 5×105 EG-7 tumour cells 6 days previously. Groups were CD8 T cells alone: 12×106 OTI T cells; CD8/CD4 Th2∶7×106 OTI T cells +5×106 OTII; CD8/CD4 Th1∶7×106 OTI T cells +5×106 OTII; CD4 Th1 alone: 12×106; untreated: EG-7 tumour cells alone. Mice were monitored until appearance of terminal symptoms (see Methods), at which point they were euthanised. Survival curves represent accumulated data from 2 experiments with 8–12 mice for all groups except CD4 Th1 alone (6 mice). There was a statistically significant difference between CD4 (Th1 or Th2) co-transferred groups and CD8 T cells alone (P<0.05, t-test) at up to 32 days post-implantation of tumour. At the termination of the experiment at 56 days post-implantation, there was a statistically significant difference for mice adoptively transferred with T cells and tumour alone (CD4 Th1 or Th2: P<0.001; CD8 P<0.05, t-test).